PureTech Health PLC

NASDAQ PRTC

Data sourced from

and

Download Data

PureTech Health PLC Liabilities to Equity Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -50.62%

PureTech Health PLC Liabilities to Equity Ratio 1 year YoY Change (%) is -50.62% for the Trailing 12 Months (TTM) ending March 31, 2024, a -1,756.33% change year over year. The liabilities to equity ratio, also known as the leverage ratio, measures the proportion of a company's total liabilities to its shareholders' equity. It is calculated by dividing the total liabilities by the shareholders' equity. This ratio provides insights into the extent to which a company relies on debt financing compared to equity financing. A higher ratio indicates higher financial leverage, which can amplify both returns and risks for the company's shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

PureTech Health PLC Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 0.55, a 3.06% change year over year.
PureTech Health PLC Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 0.53, a 22.63% change year over year.
PureTech Health PLC Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was 0.43.

NASDAQ: PRTC

PureTech Health PLC

CEO	Ms. Daphne Zohar
IPO Date	Nov. 16, 2020
Location	United States
Headquarters	6 Tide Street, Boston, MA, United States, 02210
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends